<DOC>
	<DOCNO>NCT00151398</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , efficacy 3 dos lecozotan SR patient mild moderate Alzheimer 's Disease 12 week .</brief_summary>
	<brief_title>Study Evaluating Lecozotan SR Mild Moderate Alzheimer 's Disease ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Diagnosis probable AD accord NINCDSADRDA criterion . Able give inform consent . Patient ` caregiver must consent participate study . Use medication cognitive enhancement within 3 month baseline . Significant neurologic disease AD may affect cognition .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>